Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.01 USD
Change Today -0.09 / -2.90%
Volume 35.6K
As of 10:52 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$3.10
Previous Close
$3.10
Day High
$3.20
Day Low
$3.01
52 Week High
08/4/14 - $20.75
52 Week Low
07/31/15 - $2.60
Market Cap
21.6M
Average Volume 10 Days
98.4K
EPS TTM
$-4.48
Shares Outstanding
7.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson’s disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

10 Employees
Last Reported Date: 04/6/15
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $220.6K
Chief Financial Officer
Total Annual Compensation: $175.0K
Vice President of Financial Operations, Treas...
Total Annual Compensation: $138.3K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $126.0K
Compensation as of Fiscal Year 2014.

amarantus bioscience holding (AMBS) Key Developments

Amarantus Bioscience Holdings, Inc Proposes Amendment to its Articles of Incorporation

Amarantus Bioscience Holdings Inc. announced that at its AGM to be held on August 3, 2015, the company has proposed to approve amendment to the company’s articles of incorporation to increase the company’s authorized shares of common stock from 13,333,334 to 35,000,000.

Amarantus Doses First Patient in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

Amarantus BioScience Holdings Inc. announced that the first patient has been dosed in the Phase 2b clinical study of the company's lead neurology therapeutic candidate eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Patient dosing was initiated by principal investigator Stuart H. Isaacson, M.D., Director of the Parkinson's Disease and Movement Disorders Center of Boca Raton, a nationally recognized leading clinical research institution renowned for its testing of new treatments for improving the symptoms of Parkinson's disease and decelerating its progression. The multi-center, 60-subject Phase 2b study in individuals with Parkinson's disease is a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical trial designed to evaluate dose response effect of repeated eltoprazine dosing on safety, tolerability and dyskinesia severity using rating scales, diaries and motion sensors. The Company expects to report top-line results from the eltoprazine Phase 2b study in the first half of 2016.

Amarantus BioScience Holdings Enters into Securities Purchase Agreement with Institutional Investor

On July 1, 2015, Amarantus BioScience Holdings Inc. entered into a securities purchase agreement with an institutional investor pursuant to which such investor purchased an aggregate of $650,000 in principal amount of 12% promissory notes due April 2, 2016. The principal amount of the notes shall accrue interest at a rate equal to 12% per annum, of which six months' worth of interest shall be guaranteed, payable on the maturity date in cash, or, at the company's option, in common stock or a combination thereof. At any time upon ten days written notice to the investor, the company may prepay any portion of the principal amount of the notes and any accrued and unpaid interest at an amount equal to 110% of the then outstanding principal amount of the notes and guaranteed interest, 10% of which may be paid in cash or, at the company's option, in common stock or a combination thereof. Within 3 business days following the consummation of a qualified financing, the company shall prepay the entire principal amount of the note then outstanding and any accrued and unpaid interest, at an amount equal to 110% of the then outstanding principal amount of the notes and guaranteed interest, 10% of which may be paid in cash or, at the company's option, in common stock or a combination thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $3.01 USD -0.09

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.